Welcome to NGC. Skip directly to: Search Box, Navigation, Content.
A direct comparison of the European Federation of Neurologic Studies (EFNS) and Scottish Intercollegiate Guidelines Network (SIGN) recommendations for the assessment and diagnosis of Alzheimer's disease (AD) and related dementias is provided in the tables below.
Following the content comparison tables, the areas of agreement and areas of difference among the guidelines are identified.
TABLE 5: EVIDENCE RATING SCHEMES AND REFERENCES | |
---|---|
EFNS (2007) |
Evidence Classification Scheme for a Diagnostic Measure Class I: A prospective study in a broad spectrum of persons with the suspected condition, using a "gold standard" for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy Class II: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by "gold standard") compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy Class III: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation Class IV: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls) Evidence Classification Scheme for a Therapeutic Intervention Class I: An adequately powered prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population or an adequately powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations. The following are required:
Class II: Prospective matched-group cohort study in a representative population with masked outcome assessment that meets a-e above or a randomized, controlled trial in a representative population that lacks one criteria a-e Class III: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment Class IV: Evidence from uncontrolled studies, case series, case reports, or expert opinion Rating of Recommendations for a Diagnostic Measure Level A rating (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies. Level B rating (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence. Level C rating (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies. Rating of Recommendations for a Therapeutic Intervention Level A rating (established as effective, ineffective, or harmful) requires at least one convincing class I study or at least two consistent, convincing class II studies. Level B rating (probably effective, ineffective, or harmful) requires at least one convincing class II study or overwhelming class III evidence. Level C rating (possibly effective, ineffective, or harmful) requires at least two convincing class III studies. Good Practice Points Where there was a lack of evidence but consensus was clear, the Task Force has stated their opinion as good practice points. |
SIGN (2006) |
Levels of Evidence 1++: High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias 1+: Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias 1-: Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias 2++: High quality systematic reviews of case control or cohort studies 2+: Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2-: Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3: Non-analytic studies (e.g., case reports, case series) 4: Expert opinion Grades of Recommendations Note: The grade of recommendation relates to the strength of the evidence on which the recommendation is based. It does not reflect the clinical importance of the recommendation. Grade A: At least one meta-analysis, systematic review of randomized controlled trials (RCTs), or RCT rated as 1++ and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results Grade B: A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+ Grade C: A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2++ Grade D: Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+ Good Practice Points: Recommended best practice based on the clinical experience of the guideline development group. |
EFNS and SIGN agree that a detailed medical history is an important part of the diagnostic assessment and should include the mode of onset, pattern of progression, and cognitive domains affected. There is also agreement that, given that a person with dementia may not be able to give a fully accurate history, the history should be supplemented by an independent informant when possible.
The guidelines agree that the diagnosis of a dementia syndrome can only be made in terms of probability. Both groups agree that the DSM-IIIR/DSM-IV and NINCDS-ADRDA criteria have reasonably good diagnostic accuracy with a sensitivity of approximately 80% for probable AD, and that they are appropriate criteria to use for the diagnosis of probable AD. For the diagnosis of VaD, both groups cite the NINDS-AIREN criteria, with EFNS noting that criteria achieved a low sensitivity (43%), but a good specificity (95%) in the only published class I study. In addition to the NINDS-AIREN criteria, SIGN also recommends the Hachinski Ischaemic Scale. There is agreement that it may be common for patients to present with both AD and vascular pathology, and that mixed pathologies and the prevalent findings of vascular lesions in all patients with dementia add to the complexity of the diagnosis of VaD.
EFNS and SIGN also discuss diagnostic criteria for DLB and FTD. EFNS does not provide specific recommendations, but notes that Consortium for DLB criteria showed rather low sensitivities in class I and II studies. With regard to FTD, they do not address any specific diagnostic criteria, stating that specific sets of pathological findings have not been associated with specific clinical syndromes. According to SIGN, while the clinical criteria for DLB (Consortium for DLB criteria) and FTD (Lund-Manchester criteria) are not closely associated with neuropathological diagnoses, they can still provide useful differentiating clinical features and should be considered in clinical assessment.
Both groups agree that cognitive assessment is central to the diagnosis of dementias and should be performed in all patients. Both groups cite the MMSE as an appropriate global cognitive testing tool. SIGN notes that initial cognitive testing can be improved by the use of Addenbrooke's Cognitive Examination, a more comprehensive measure of cognitive function that incorporates the MMSE. The 7-Minute Screen and Clinical Dementia Rating (CDR) tests can be useful for the detection of dementia, according to EFNS. They add that the Mattis Dementia Rating Scale, however, is more appropriate for the assessment and follow-up of FTD and fronto-subcortical dementias. Both groups also agree that informant-based questionnaires completed by someone who knows the patient, such as the IQCODE, can be useful in the detection of dementia.
Both groups also agree that more advanced neuropsychological testing should also be used in the diagnosis of dementia. According to SIGN, it is possible to detect even very early AD using neuropsychological testing, and it also aids in the differential diagnosis of dementia. EFNS emphasizes that detailed testing of the main cognitive domains including memory, executive functions, and instrumental functions should be performed. To assess memory function, EFNS cites the Rey Auditory Verbal Learning Test (RAVLT), the Memory Impairment Scale (MIS), and the "5-Word" test. The Wisconsin card sorting test, the Trail Making test, the Stroop test, verbal fluency tests, and the digit ordering test are currently used to assess executive function deficits, according to EFNS.
The groups agree that the presence of behavioral and psychological symptoms of dementia (e.g., hallucinations, delusions, behavioral disturbances) must be assessed for. EFNS notes that several informant-based instruments have been designed for this purpose. Suitable scales cited by EFNS include the Neuropsychiatric Inventory (NPI), Behavior Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) and the Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD).
The groups agree that assessment of co-morbidity is important in the evaluation of patients with suspected dementia. Depression is cited by both groups as a comorbidity that should be screened for. EFNS also notes that cardiovascular disease, infections, adverse effects of drugs, delirium, falls, incontinence, and anorexia are frequently observed co-morbidities or complications. Refer to Areas of Differences for additional information.
EFNS and SIGN agree that imaging can be used to detect reversible causes of dementia and to aid in the differential diagnosis of dementia. They further agree that structural imaging tests (e.g., CT, MRI) should be routinely used in the diagnostic evaluation of patients with suspected dementia. There is also agreement that functional imaging tests (e.g., SPECT, PET) can be useful in conjunction with functional imaging tests in cases where there is diagnostic uncertainty.
Neither group recommends routine use of CSF or EEG investigations in the diagnosis of dementia. The groups agree, however, that CSF (specifically assessment of the 14-3-3 protein) and EEG investigations can be useful where CJD is suspected. EFNS also recommends CSF analysis with routine cell count, protein, glucose and protein electrophoresis in patients with a clinical suspicion of certain diseases and in patients with atypical clinical presentations. They add that CSF total tau, phospho-tau and Ab42 can be used as an adjunct in cases of diagnostic doubt.
According to SIGN, reversible causes of dementia are very rare and very few cases of reversible or partially reversible dementia have been detected by batteries of routine physical investigations. They add that there is no evidence that routine batteries of laboratory tests improve the accuracy of the clinical diagnosis of dementia. SIGN therefore recommends that physical investigations including laboratory tests should be selected on clinical grounds according to history and clinical circumstances.
In contrast to SIGN, EFNS states that the following blood tests are generally proposed as mandatory tests for all patients at first evaluation, both as a potential cause of cognitive impairment or as co-morbidity: blood sedimentation rate, complete blood cell count, electrolytes, calcium, glucose, renal and liver function tests, and thyroid stimulating hormone. They add that more extensive tests will often be required, e.g. vitamin B12 and serological tests for syphilis, HIV, and Borrelia, in individual cases.
Only EFNS provides recommendations for other investigations: genetic testing and tissue biopsy. With regard to genetic testing, they note that screening for known pathogenic mutations can be undertaken in patients with appropriate phenotype or a family history of an autosomal dominant dementia. They add that pre-symptomatic testing may be performed in adults where there is a clear family history, and when there is a known mutation in an affected individual to ensure that a negative result is clinically significant. With regard to tissue biopsy, EFNS states that it can provide a specific diagnosis in some rare dementias. They note that both types of investigations should only be undertaken in specialist centres.
This synthesis was prepared by ECRI on September 27, 2006. It was reviewed by SIGN on October 23, 2006. This synthesis was updated in June 2009 to remove recommendations from AAN and AMDA, and to add EFNS recommendations. The information was verified by EFNS on July 1, 2009.
Internet citation: National Guideline Clearinghouse (NGC). Guideline synthesis: Assessment and diagnosis of Alzheimer's disease and related dementias. In: National Guideline Clearinghouse (NGC) [website]. Rockville (MD): 2006 Nov (revised 2009 Jul). [cited YYYY Mon DD]. Available: http://www.guideline.gov.